

해외 바이오의약품 임상 현황 (2020.12.14~2020.12.20)

한국바이오의약품협회, 2020.12.22.
출처: ClinicalTrials.gov

○ 미국 21건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04220190	RAPA-501 Therapy for ALS	Amyotrophic Lateral Sclerosis	Biological: RAPA-501 Autologous T cells	Rapa Therapeutics LLC Massachusetts General Hospital Hackensack Meridian Health	Phase 1 Phase 2
NCT04669808	Open Label, Dose Escalation Study for the Safety and Efficacy of STP705 in Adult Patients With Basal Cell Carcinoma	Basal Cell Carcinoma	Drug: STP705	Sirnaomics Amarex Clinical Research	Phase 2
NCT04667052	A Study to Compare Two Different Subcutaneously-administered JNJ-64304500 Formulations in Healthy Participants	Healthy	Drug: JNJ 64304500	Janssen Research & Development, LLC	Phase 1
NCT04664738	PEP on a Skin Graft Donor Site Wound	Skin Graft	Biological: 10% PEP Drug: TISSEEL Biological: 20% PEP	Steven L. Moran Mayo Clinic	Phase 1
NCT04661384	Brain Tumor-Specific Immune Cells (IL13Ralpha2-CAR T Cells) for the Treatment of Leptomeningeal Glioblastoma, Ependymoma, or Medulloblastoma	Leptomeningeal Metastases	Biological: IL13Ralpha2-specific Hinge-optimized 41BB-co-stimulatory CAR Truncated CD19-expressing Autologous T-Lymphocytes	City of Hope Medical Center National Cancer Institute (NCI)	Phase 1
NCT04486001	Study of Intravenous Administration of Allogeneic Adipose Stem Cells for COVID-19	Covid19	Biological: PSC-04	Sorrento Therapeutics, Inc. VetStem Biopharma, Inc. Fresno Community Hospital and Medical Center	Phase 1
NCT04452955	A Study to Assess Safety and Efficacy of PRL3-Zumab in Patients With Solid Tumors	Solid Tumor	Biological: PRL3-zumab	Intra-IMMUSG Pte Ltd Parexel	Phase 2
NCT04348747	Dendritic Cell Vaccines Against Her2/Her3, Cytokine Modulation Regimen, and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer	Anatomic Stage IV Breast Cancer AJCC v8 Metastatic Malignant Neoplasm in the Brain Metastatic Triple-Negative Breast Carcinoma Prognostic Stage IV Breast Cancer AJCC v8	Biological: Anti-HER2/HER3 Dendritic Cell Vaccine Drug: Celecoxib Biological: Pembrolizumab Biological: Recombinant Interferon Alfa-2b Drug: Rintatolimod	Roswell Park Cancer Institute National Cancer Institute (NCI)	Phase 2
NCT04006652	ApoGraft for the Prevention of Acute Graft Versus Host Disease in Haploidentical Hematopoietic Cell Transplant Recipients	Acute Graft Versus Host Disease Haploidentical Hematopoietic Stem Cell Transplant	Drug: ApoGraft	Washington University School of Medicine Collect Biotechnology	Phase 1
NCT04636229	Efficacy of Amniotic Suspension Allograft in Patients With Osteoarthritis of the Knee	Knee Osteoarthritis	Biological: Amniotic Suspension Allograft Drug: Placebo	Organogenesis Premier Research International LLC	Phase 3
NCT04448834	Blinicyto Amgen Acrotech BioPharma PH2 Blincyto Marqibo R/R Philadelphi CD19+ ALL	B-cell Acute Lymphoblastic Leukemia	Drug: Blinatumomab	David Rizzieri, MD Amgen Acrotech Biopharma LLC Duke University	Phase 2
NCT04666441	A Study to Assess the Virologic Efficacy of REGN10933+REGN10987 Across Different Dose Regimens in Adult Outpatients With SARS-CoV-2 Infection	COVID-19	Drug: REGN10933+REGN10987 combination therapy Drug: Placebo	Regeneron Pharmaceuticals	Phase 2
NCT04598451	A Study to Assess the Efficacy and Safety of a Subcutaneous Formulation of Efgartigimod PH20 SC in Adults With Pemphigus (Vulgaris or Foliaceus)	Pemphigus Vulgaris Pemphigus Foliaceus	Biological: efgartigimod PH20 SC Other: Placebo Drug: prednisone	argenx	Phase 3
NCT04676737	Phase 2 Study of TTHX1114(NM141) in Patients Undergoing DWEK/DSO	Fuchs' Endothelial Dystrophy Fuchs Dystrophy Fuchs	Drug: TTHX1114(NM141)	Trefoil Therapeutics, Inc.	Phase 2
NCT04628780	Study to Test the Safety and Tolerability of PF-07209960 in Advanced or Metastatic Solid Tumors	Non-small-cell Lung Cancer Squamous Cell Carcinoma of the Head and Neck Renal Cell Carcinoma Urothelial Carcinoma Colorectal Carcinoma Ovarian Carcinoma	Biological: PF-07209960	Pfizer	Phase 1
NCT04655807	A Study of JNJ-64304500 as Add-on Therapy in Participants With Active Crohn's Disease	Crohn Disease	Drug: JNJ-64304500 Drug: Placebo Drug: Adalimumab Drug: Ustekinumab	Janssen Research & Development, LLC	Phase 2
NCT04640623	A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy	Urinary Bladder Neoplasms	Drug: TAR-200 Drug: Cetrelimab	Janssen Research & Development, LLC	Phase 2
NCT04544436	A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)	Multiple Sclerosis	Drug: Ocrelizumab Drug: Antihistamine Drug: Methylprednisolone	Hoffmann-La Roche	Phase 3
NCT04408638	A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma	Diffuse Large B-cell Lymphoma	Drug: Obinutuzumab Drug: Glofitamab Drug: Rituximab Drug: Tocilizumab Drug: Gemcitabine Drug: Oxaliplatin	Hoffmann-La Roche	Phase 3
NCT04673266	Using Romiplostim to Treat Low Platelet Counts During Chemotherapy in People With Lymphoma	Lymphoma Patients Thrombocytopenia	Drug: Romiplostim	Memorial Sloan Kettering Cancer Center Amgen	Phase 2
NCT04204616	A Long-term Study of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)	Prurigo Nodularis	Drug: Nemolizumab	Galderma R&D	Phase 3

해외 바이오의약품 임상 현황 (2020.12.14~2020.12.20)

한국바이오의약품협회, 2020.12.22.
출처: ClinicalTrials.gov

○ 영국 5건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04671017	Dose Finding Study to Evaluate Safety, Tolerability and Immunogenicity of an Inactivated Adjuvanted Sars-Cov-2 Virus Vaccine Candidate Against Covid-19 in Healthy Adults	Sars-Cov-2 Virus Infection	Biological: VLA2001	Valneva Austria GmbH National Institute for Health Research, United Kingdom	Phase 1 Phase 2
NCT04673630	Study to Evaluate the Pharmacokinetics of Tezepelumab in Children With Asthma	Asthma	Biological: Tezepelumab	AstraZeneca Amgen	Phase 1
NCT04544436	A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)	Multiple Sclerosis	Drug: Ocrelizumab Drug: Antihistamine Drug: Methylprednisolone	Hoffmann-La Roche	Phase 3
NCT04408638	A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma	Diffuse Large B-cell Lymphoma	Drug: Obinutuzumab Drug: Glofitamab Drug: Rituximab Drug: Tocilizumab Drug: Gemcitabine Drug: Oxaliplatin	Hoffmann-La Roche	Phase 3
NCT04204616	A Long-term Study of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)	Prurigo Nodularis	Drug: Nemolizumab	Galderma R&D	Phase 3

○ 프랑스 5건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04547504	pEmbrolizumab verSus chemotherapy and pEmbrolizumab in Non-small-cell Lung Cancers (NSCLC) With PDL1≥50 %	Non-small-cell Lung Cancer	Drug: Pembrolizumab Drug: Pembrolizumab and Chemotherapy drugs	University Hospital, Brest Groupe Français de Pneumo-Cancérologie	Phase 3
NCT04640623	A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy	Urinary Bladder Neoplasms	Drug: TAR-200 Drug: Cetrelimab	Janssen Research & Development, LLC	Phase 2
NCT04204616	A Long-term Study of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)	Prurigo Nodularis	Drug: Nemolizumab	Galderma R&D	Phase 3
NCT04544436	A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)	Multiple Sclerosis	Drug: Ocrelizumab Drug: Antihistamine Drug: Methylprednisolone	Hoffmann-La Roche	Phase 3
NCT04655807	A Study of JNJ-64304500 as Add-on Therapy in Participants With Active Crohn's Disease	Crohn Disease	Drug: JNJ-64304500 Drug: Placebo Drug: Adalimumab Drug: Ustekinumab	Janssen Research & Development, LLC	Phase 2

○ 독일 7건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04652102	A Study to Determine the Safety and Efficacy of SARS-CoV-2 mRNA Vaccine CVnCoV in Adults	Covid19 SARS-CoV-2	Biological: CVnCoV Biological: Placebo	CureVac AG	Phase 2 Phase 3
NCT04674189	A Study to Evaluate the Safety and Immunogenicity of Vaccine CVnCoV in Healthy Adults in Germany	Coronavirus Covid19 SARS-CoV-2 Severe Acute Respiratory Syndrome	Biological: CVnCoV Vaccine Drug: Placebo	CureVac AG	Phase 3
NCT04640623	A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy	Urinary Bladder Neoplasms	Drug: TAR-200 Drug: Cetrelimab	Janssen Research & Development, LLC	Phase 2
NCT04544436	A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)	Multiple Sclerosis	Drug: Ocrelizumab Drug: Antihistamine Drug: Methylprednisolone	Hoffmann-La Roche	Phase 3
NCT04655807	A Study of JNJ-64304500 as Add-on Therapy in Participants With Active Crohn's Disease	Crohn Disease	Drug: JNJ-64304500 Drug: Placebo Drug: Adalimumab Drug: Ustekinumab	Janssen Research & Development, LLC	Phase 2
NCT04204616	A Long-term Study of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)	Prurigo Nodularis	Drug: Nemolizumab	Galderma R&D	Phase 3
NCT04408638	A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma	Diffuse Large B-cell Lymphoma	Drug: Obinutuzumab Drug: Glofitamab Drug: Rituximab Drug: Tocilizumab Drug: Gemcitabine Drug: Oxaliplatin	Hoffmann-La Roche	Phase 3

해외 바이오의약품 임상 현황 (2020.12.14~2020.12.20)

한국바이오의약품협회, 2020.12.22.
출처: ClinicalTrials.gov

○ 중국 8건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT03985891	The Efficacy of JS001 Combined With Chemotherapy in Patients With Locally Advanced Colon Cancer	Colonic Neoplasms Chemotherapy Effect	Drug: Anti-PD-1 Monoclonal Antibody JS001 Drug: Chemotherapy	Xiangya Hospital of Central South University	Phase 1 Phase 2
NCT04665609	Thermal Ablation Combined With Anlotinib and TQB2450 Solution for HCC	Hepatocellular Carcinoma Thermal Ablation Anlotinib PDL-1	Drug: Anlotinib and TQB2450 solution Drug: TQB2450 solution	Chinese PLA General Hospital	Phase 3
NCT04663035	Ablation Plus Tislelizumab Versus Ablation Alone for Intrahepatic Recurrent Early Stage HCC	Recurrent Hepatocellular Carcinoma	Drug: Tislelizumab Procedure: Ablation	Ming Zhao Sun Yat-sen University	Phase 2
NCT04646590	A Phase III Clinical Trial to Determine the Safety and Efficacy of ZF2001 for Prevention of COVID-19	Prevention of COVID-19 Safety and Efficacy of COVID-19	Biological: Recombinant new coronavirus vaccine (CHO cell) group Biological: Recombinant new coronavirus vaccine (CHO cells) placebo group	Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.	Phase 3
NCT04143984	Carbon-Ion Radiotherapy Plus Camrelizumab for Locally Recurrent Nasopharyngeal Carcinoma	Nasopharyngeal Carcinoma	Radiation: Carbon-ion radiotherapy Drug: Camrelizumab	Shanghai Proton and Heavy Ion Center	Phase 2
NCT04672928	A Clinical Study to Evaluate the Efficacy and Safety of IBI318 in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel in Patients With Small Cell Lung Cancer Who Have Failed First-line or Above Chemotherapies	Small Cell Lung Carcinoma	Drug: paclitaxel Biological: IBI318	Innovent Biologics (Suzhou) Co. Ltd.	Phase 1
NCT04308785	Atezolizumab Consolidation in Limited Stage Small Cell Lung Cancer	Carcinoma, Small Cell Lung	Drug: Atezolizumab Drug: Cisplatin Drug: Carboplatin Drug: Etoposide	Hoffmann-La Roche	Phase 2
NCT04408638	A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma	Diffuse Large B-cell Lymphoma	Drug: Obinutuzumab Drug: Glofitamab Drug: Rituximab Drug: Tocilizumab Drug: Gemcitabine Drug: Oxaliplatin	Hoffmann-La Roche	Phase 3

○ 일본 2건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04580407	Efficacy and Safety Evaluation of B-Domain Deleted Recombinant Porcine Factor VIII (rpFVIII, TAK-672), in Japanese Participants With Acquired Hemophilia A (AHA)	Acquired Hemophilia A	Biological: TAK-672	Takeda	Phase 2 Phase 3
NCT04640623	A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy	Urinary Bladder Neoplasms	Drug: TAR-200 Drug: Cetrelimab	Janssen Research & Development, LLC	Phase 2